Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome

A.Y. Thijssen*, C.H. Clemens, V. Vankerckhoven, H. Goossens, D.M. Jonkers, A.A. Masclee

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND AND AIMS: Meta-analyses point to a modest but significant effect of probiotics on symptoms in irritable bowel syndrome (IBS). We aimed to assess the effect of the probiotic Lactobacillus casei Shirota (LcS) on symptoms and quality of life in IBS patients in a randomized, double-blind, placebo-controlled intervention study. MATERIALS AND METHODS: IBS patients (Rome II) between 18 and 65 years of age were included. The study consisted of an 8-week intervention period in which the participants received probiotic (LcS) or placebo twice daily, followed by an 8-week follow-up period. Symptom diaries and quality of life were scored at weeks 0, 8 and 16. The primary outcome parameter was a decrease of at least 30% in a composite mean symptom score (MSS) at week 8 on the basis of an intention-to-treat analysis. RESULTS: Thirty-nine individuals (67% women) were included in the probiotic group and 41 individuals (71% women) were included in the placebo group. After the intervention period, the mean relative improvement did not reach 30% for MSS or any individual symptom score. After follow-up (week 16), a mean improvement of at least 30% was achieved for MSS in the probiotic group, but no significant difference was found between both treatment groups (mean+/-SD: 34+/-7%; 13+/-8%, P=0.06). CONCLUSION: After probiotic treatment with LcS, no improvement of 30% in MSS was observed after 8 weeks.
Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalEuropean Journal of Gastroenterology & Hepatology
Volume28
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • CLINICAL-TRIAL
  • DOUBLE-BLIND
  • FUNCTIONAL GASTROINTESTINAL DISORDERS
  • INTESTINAL MICROFLORA
  • PLACEBO-RESPONSE
  • PROBIOTICS
  • QUALITY-OF-LIFE
  • RANDOMIZED CONTROLLED-TRIAL
  • STRAIN SHIROTA
  • SYMPTOMS

Cite this